Showing 3131-3140 of 4166 results for "".
- Stealth BioTherapeutics Announces Poster Presentation at ARVOhttps://modernod.com/news/stealth-biotherapeutics-announces-poster-presentation-at-arvo/2479132/Stealth BioTherapeutics announced that the company will have a poster presentation with a live discussion at the upcoming 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting, which is being held May 1-7, 2021. The poster showcases
- Lantronix Contributes to eSight Design, Enabling Individuals With Serious Visual Impairment to Seehttps://modernod.com/news/lantronix-contributes-to-esight-design-enabling-individuals-with-serious-visual-impairment-to-see/2479082/Lantronix announced that its engineering services team supported eSight Corp. in the development of an enhanced vision device that enables individuals with serious visual impairment to see. eSight was recently recognized as a manufacturer of the Best Wearable/Healthcare Hardware/Soft
- World Council of Optometry Passes Resolution Calling for a Standard of Care for Myopia Managementhttps://modernod.com/news/world-council-of-optometry-passes-resolution-calling-for-a-standard-of-care-for-myopia-management/2479073/The World Council of Optometry (WCO) Board of Directors unanimously approved a resolution advising optometrists to incorporate a standard of care for myopia management within their practices. “Myopia is increasing at an alarming rate, as are the risks for vision impairment associated with
- Ocuphire Initiates ZETA-1 Phase 2 Clinical Trial Investigating APX3330 in Diabetic Retinopathyhttps://modernod.com/news/ocuphire-initiates-zeta-1-phase-2-clinical-trial-investigating-apx3330-in-diabetic-retinopathy/2479060/Ocuphire Pharma announced that it has screened the first patient in ZETA-1, a phase 2 trial to evaluate APX3330 in non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (PDR). Effects on diabetic macular edema will be explored as a secondary outcome. A number o
- Oasis Medical Launches Cyber Platform MY OASIS to Support Dry Eye Clinicshttps://modernod.com/news/oasis-medical-launches-cyber-platform-my-oasis-to-support-dry-eye-clinics/2479021/Oasis Medical is formally launching its new patented cyber platform MY OASIS at SECO International 2021, booth #722. MY OASIS is a cyber platform for eye care providers to build their brand as a dry eye resourc
- ProQR Announces Positive Results From Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trialshttps://modernod.com/news/proqr-announces-positive-results-from-clinical-trial-of-qr-421a-in-usher-syndrome-and-plans-to-start-pivotal-trials/2479006/ProQR Therapeutics announced results from a planned analysis of its phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations. In the trial, QR-421a demonstrated benefit on multiple measures of v
- Bio-Tissue Receives FDA Clearance to Proceed with Clinical Study Using Investigational New Drug TTBT01https://modernod.com/news/bio-tissue-receives-fda-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-ttbt01/2478924/Bio-Tissue announced that its parent company TissueTech had received clearance from the FDA to proceed with a phase 2 study using morselized Cryopreserved Amniotic Membrane (CAM) and Cryopreserved Umbilical Cord (CUC) investigational new drug (IND) TTBT01. This clearance represents another milest
- Moderna’s Variant-Specific COVID-19 Vaccine Candidate Ready for Clinical Testinghttps://modernod.com/news/modernas-variant-specific-covid-19-vaccine-candidate-ready-for-clinical-testing/2478914/Moderna said that it has manufactured the initial batch of an updated version of its COVID-19 vaccine designed to better protect against the B.1.351 variant of SARS-CoV-2 first identified in South Africa. The company indicated late last month that it would be working on the variant-specific boost
- Ocular Therapeutix Presents Interim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients With Glaucomahttps://modernod.com/news/ocular-therapeutix-presents-interim-topline-data-from-the-phase-1-clinical-trial-of-otx-tic-in-patients-with-glaucoma/2478784/Ocular Therapeutix announced plans to present data on OTX-TIC, a travoprost intracameral implant for the treatment of patients with primary open angle glaucoma or ocular hypertension, at the Glaucoma 360 New Horizons Forum being held virtually on January 30. As part of the event, Michael Goldstei
- Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopiahttps://modernod.com/news/eyenovia-announces-first-patients-enrolled-in-phase-3-study-of-microline-for-presbyopia/2478667/Eyenovia announced that the first set of patients has been enrolled in the company’s phase 3 VISION-1 study of MicroLine, its proprietary pilocarpine formulation delivered via its Optejet dispenser, for the